×
About 69,603 results

ALLMedicine™ Tuberculosis Center

Research & Reviews  24,680 results

Preparation and Evaluation of Low-Dose Calcitriol Dry Powder Inhalation as Host-Directe...
https://doi.org/10.1007/s11095-022-03360-5
Pharmaceutical Research; Reddy DVS, Shafi H et. al.

Aug 13th, 2022 - It is unclear whether Vitamin D is efficacious as a host-directed therapy (HDT) for patients of tuberculosis (TB). We investigated pulmonary delivery of the active metabolite of Vitamin D3, i.e., 1, 25-dihydroxy vitamin D3 (calcitriol) in a mouse ...

Drug susceptibility profiling and genetic determinants of drug resistance in Mycobacter...
https://doi.org/10.1371/journal.pone.0267320
PloS One; Daneshfar S, Khosravi AD et. al.

Aug 13th, 2022 - Among Non-tuberculous mycobacteria (NTM) which generally cause opportunistic infections, especially in immunocompromised hosts, Mycobacterium simiae (M. simiae) is one of the most important NTM, associated with pulmonary disease. The main concern ...

Evaluation of trace calls by Xpert MTB/RIF ultra for clinical management in low TB burd...
https://doi.org/10.1371/journal.pone.0272997
PloS One; Amedeo A, Beci G et. al.

Aug 13th, 2022 - Clinical interpretation of trace results by Xpert MTB/RIF Ultra assay (Ultra) used as an initial diagnostic test for tuberculosis (TB) may be challenging. The aim of the study was to evaluate the frequency and epidemiology of trace readouts in rou...

Health Status of Afghan Refugees in Europe: Policy and Practice Implications for an Opt...
https://doi.org/10.3390/ijerph19159157
International Journal of Environmental Research and Publi... Matsangos M, Ziaka L et. al.

Aug 13th, 2022 - Four decades of civil war, violence, and destabilisation have forced millions of Afghans to flee their homes and to move to other countries worldwide. This increasing phenomenon may challenge physicians unfamiliar with the health status of this po...

Strengthening resistance testing for tuberculosis in India - Investment cost, throughpu...
https://doi.org/10.1016/j.tube.2022.102245
Tuberculosis (Edinburgh, Scotland); Bashir S, Sarin S et. al.

Aug 13th, 2022 - A lack of laboratory capacity for drug-resistant tuberculosis (DR-TB) testing is a major barrier to DR-TB control. To overcome this barrier, the Central Tuberculosis Division (CTD), Ministry of Health and Family Welfare (MoHFW), Government of Indi...

see more →

Guidelines  28 results

WHO consolidated guidelines on tuberculosis Module 5: Management of tuberculosis in children and adolescents
https://www.who.int/publications/i/item/9789240046764
World Health Organization (WHO)

Mar 21st, 2022 - The Updated guidelines on Management of tuberculosis in children and adolescents include new recommendations that cover diagnostic approaches for TB, shorter treatment for children with non-severe drug-susceptible TB, a new option for the treatmen...

Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Su...
https://doi.org/10.15585/mmwr.mm7108a1
MMWR. Morbidity and Mortality Weekly Report; Carr W, Kurbatova E et. al.

Feb 25th, 2022 - On May 5, 2021, CDC's Tuberculosis Trials Consortium and the National Institutes of Health (NIH)-sponsored AIDS Clinical Trials Group (ACTG) published results from a randomized controlled trial indicating that a 4-month regimen containing rifapent...

Cancer immunotherapy in special challenging populations: recommendations of the Advisor...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009216
Journal for Immunotherapy of Cancer; Gonzalez-Cao M, Puertolas T et. al.

Mar 31st, 2021 - Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other t...

Multisystem inflammatory syndrome in an adult with SARS-CoV-2 infection.
https://doi.org/10.1016/j.arbres.2020.03.021
European Heart Journal. Cardiovascular Imaging; Chowdhary A, Joy E et. al.

Sep 6th, 2020 - New evidence and knowledge about the clinical management of drug-resistant tuberculosis (TB) in the last 3 years, makes it necessary to update the recent guideline published by SEPAR in 2017, mainly in relation to new diagnostic methods, drug clas...

2019 update of the European AIDS Clinical Society Guidelines for treatment of people li...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754379
HIV Medicine; Ryom L, Cotter A et. al.

Sep 5th, 2020 - The European AIDS Clinical Society (EACS) Guidelines cover key aspects of HIV management with major updates every two years. The 2019 Guidelines were extended with a new section focusing on drug-drug interactions and other prescribing issues in pe...

see more →

Drugs  428 results see all →

Clinicaltrials.gov  1,337 results

Statin Adjunctive Therapy for TB (StAT- TB)
https://clinicaltrials.gov/ct2/show/NCT03456102

Aug 12th, 2022 - There is an urgent need for novel therapies to shorten TB treatment and improve long-term lung function outcomes. Host-directed therapies (HDT) have received significant attention recently given the ability of M. tuberculosis to subvert host immun...

NexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in Tuberculosis
https://clinicaltrials.gov/ct2/show/NCT02371681

Aug 12th, 2022 - Early bactericidal activity (EBA), which measures decline in serial sputum colony forming unit (CFU) counts over the first 2-14 days of treatment, has been used extensively as a means of initially evaluating the potency of individual or combinatio...

Training Protocol on the Natural History of Tuberculosis
https://clinicaltrials.gov/ct2/show/NCT01212003

Aug 12th, 2022 - Mycobacterium tuberculosis (MTB) is a slow-growing bacterium that establishes latent infection in millions of persons worldwide, but only leads to disease in 10% or less of these individuals. It typically causes pneumonia, however dissemination to...

A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis
https://clinicaltrials.gov/ct2/show/NCT05014360

Aug 12th, 2022 - Familial adenomatous polyposis (FAP) is the most common polyposis syndrome. It is an autosomal dominant inherited disorder characterized by the early onset of hundreds to thousands of adenomatous polyps throughout the colon. JNJ-64251330 (lorpucit...

A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
https://clinicaltrials.gov/ct2/show/NCT05071664

Aug 12th, 2022 - PsA is a chronic inflammatory multi-faceted disease that impacts the peripheral and axial joints, soft tissues, and skin. Guselkumab is a fully human monoclonal antibody (mAb) directed against the p19 subunit of interleukin (IL)-23, blocks the bin...

see more →

News  1,337 results

Ustekinumab Becomes Second Biologic Approved for PsA in Kids
https://www.medscape.com/viewarticle/978462

Aug 2nd, 2022 - The US Food and Drug Administration has approved the dual interleukin (IL)-12 and IL-23 inhibitor ustekinumab (Stelara) for the treatment of juvenile psoriatic arthritis (jPsA) in patients aged 6 years and older, according to an August 1 announcem...

Denying Refugees and Migrants Healthcare Violates Rights, WHO Says
https://www.medscape.com/viewarticle/977582

Jul 21st, 2022 - (Reuters) - Millions of migrants and refugees are being denied adequate health care and should be included in the health systems of host countries as a human right, the World Health Organization said on Wednesday. In its first attempt at reviewing...

5 Things to Know About the New 4-Month TB Treatment Regimen
https://www.medscape.com/viewarticle/976570

Jul 8th, 2022 - On February 24, 2022, the Centers for Disease Control and Prevention (CDC) published new interim guidance in Morbidity and Mortality Weekly Report on a 4-month treatment regimen as an option for US patients with drug-susceptible pulmonary tubercul...

Sanofi Launches Global Health Brand With Nonprofit Treatments
https://www.medscape.com/viewarticle/976766

Jul 7th, 2022 - LONDON (Reuters) - French drugmaker Sanofi will make 30 of its treatments, including insulin, available on a not-for-profit basis in 40 lower-income countries in the first step of its plan to increase access to its medicines worldwide. The treatme...

GSK, Novartis Pledge Funds for Neglected Tropical Diseases
https://www.medscape.com/viewarticle/976095

Jun 24th, 2022 - LONDON (Reuters) - GSK and Novartis reinforced commitments on Thursday to tackle neglected tropical diseases, as world leaders and health experts gather in Rwanda to discuss ways to better combat illnesses affecting more than a billion people, mos...

see more →

Patient Education  31 results see all →